S. Harris

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

M. Gore, P. Lorigan, N. Thatcher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant interferon-alpha in malignant melanoma: current status.

M. Gore, K. Wheatley, B. Hancock, 2000, Cancer treatment reviews.

Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.

T. Lister, A. Horwich, J. Radford, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors

M. Williams, T. Lister, A. Horwich, 2013, British Journal of Cancer.

Risk of premature menopause after treatment for Hodgkin's lymphoma.

A. Horwich, J. Radford, A. Swerdlow, 2014, Journal of the National Cancer Institute.